Blood antibody patterns that appear years before symptoms could eventually enable earlier identification of people at risk for Crohn’s disease or ulcerative colitis and help predict who may develop more complicated...

Replacing some MREs and colonoscopies with point-of-care intestinal ultrasound could reduce healthcare costs, lower patient exposure to invasive or resource-intensive tests, and shrink the carbon footprint of IBD...

Pregnancy outcomes in people with IBD are linked to disease activity and treatment. This study compares outcomes across women who continued, stopped, never used, or started biologics during pregnancy, which can inform...

Anemia is common in IBD and hard to classify accurately; better blood markers can guide appropriate iron treatment and avoid delays. This study evaluates a novel marker (sHjv) alongside established tests.

This study suggests that patients with Crohn’s disease or ulcerative colitis who start ustekinumab may use fewer non-drug healthcare resources and incur lower non-medication costs over time, which could matter for...

People with IBD and a recent solid cancer face a trade-off between controlling IBD with advanced therapies (biologics or small molecules) and potential oncologic or infectious risks. This study examined real-world...

Many people with IBD also have inflammatory joint disease. This combined clinic model aimed to provide simultaneous gastroenterology and rheumatology assessment and shared decision-making, and the study reports frequent...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Communications Medicine.

This change may make starting Skyrizi more convenient for adults with Crohn's disease by allowing subcutaneous induction at home using an on‑body injector, rather than requiring clinic IV infusions. It also represents an...

Based on the title and source metadata, this appears to be a patient education related to Inflammatory bowel disease and Diet and lifestyle. The original article is from Journal of Visualized Experiments.

MSC therapy and its interaction with autophagy could point to new ways to boost cell-based treatments for IBD. For people with Crohn's disease or ulcerative colitis, this could eventually lead to different therapeutic...

IUS can provide rapid, bedside assessment and longitudinal monitoring of IBD activity, which may improve treat-to-target care. Understanding barriers and strategies for implementation matters for patients and clinicians...

The paper describes a plant-derived polysaccharide that reduced inflammation, improved barrier proteins, and shifted gut microbiota in a mouse model of ulcerative colitis—mechanisms relevant to IBD. If replicated and...

If probiotic strains can increase beneficial microbial metabolites that strengthen the gut barrier and reduce inflammation, they could point to new adjunctive strategies for IBD treatment.

Based on the title and source metadata, this appears to be a case report related to Procedures and surgery. The original article is from Radiology Case Reports.

A transcriptomic "barrier-injury" score that tracks mucosal inflammation and predicts lower odds of mucosal healing could help researchers develop biomarkers for patient stratification, prognosis, or as exploratory...

The study suggests commonly available lab tests might help identify intestinal fibrosis and strictures in Crohn’s disease using a five-marker blood-based model, which could offer a noninvasive screening option if...

A formulation that targets and sustains budesonide release in the intestine could improve local anti-inflammatory effects and reduce systemic exposure compared with standard oral formulations. If translational studies...

The study identifies a TSPO-targeting compound (koumine) that improved disease and intestinal barrier function in mouse models of ulcerative colitis and links the effect to changes in energy metabolism—an emerging area...

The study suggests a specific mechanism—modulation of the SphK1/S1P/NF-κB pathway—by which components of a traditional herbal formula may reduce intestinal inflammation and influence the gut microbiome. If validated in...

The paper points to a specific RNA-modifying protein (YTHDF2) that appears to drive inflammatory signaling and pyroptotic cell death in lab models of ulcerative colitis; targeting this pathway could open new avenues for...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Molecular...

A subcutaneous induction option means some adults with moderate–severe Crohn’s disease can begin risankizumab treatment at home rather than needing an IV infusion visit, potentially increasing convenience and access. The...

Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.

Based on the title and source metadata, this appears to be a video related to Ulcerative colitis and Medications. The original article is from hmpgloballearningnetwork.com.

The study identifies a prebiotic-encapsulated extracellular vesicle approach that reduced colitis severity and early kidney stress in a mouse model, pointing to the gut microbiota and barrier function as key mediators....

The updated official label affects dosing options, monitoring, and safety information for guselkumab in people with Crohn’s disease and ulcerative colitis, which can influence treatment decisions and routine testing.

If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher...

People hospitalized with acute severe ulcerative colitis face a high risk of steroid failure and need for rescue therapy or colectomy. This trial explores whether adding the JAK inhibitor tofacitinib to corticosteroids...

Patients and clinicians want blood or noninvasive tests that reflect what is seen on colonoscopy. This study identifies XCL1 as a blood biomarker candidate associated with endoscopic activity in Crohn's disease, though...

Accurate diagnosis and classification affect treatment choices and risks—misdiagnosis can lead to unnecessary immunosuppression, while misclassification can under-recognize severe or proximal disease that needs different...

Validated patient-reported measures help track how IBD affects daily function and well-being. A Turkish IBD-Disk gives clinicians and researchers a standardized way to measure patient-perceived disease burden and monitor...

The endoplasmic reticulum helps control cell metabolism and is implicated in conditions including metabolic disorders, cancer, and inflammatory diseases such as Crohn’s disease.

AHR signaling may influence epithelial inflammation in IBD and could be a potential target for future therapies or biomarker research. Findings are preliminary but point to IL‑8 as a responsive inflammatory mediator in...

The study describes a new small-molecule approach that reduced inflammation in mouse models of ulcerative colitis by targeting NF-κB transcription (p65 G-quadruplex). That suggests a potential future drug pathway...

This study describes a new preclinical approach to reduce inflammation in IBD by degrading NLRP3 rather than merely inhibiting it. For people following IBD therapeutic research, degraders could offer longer-lasting...

Postoperative intra-abdominal abscesses are a common, serious short-term complication after ileocecal surgery in children with Crohn’s disease and can lengthen hospital stay and delay restarting medical treatment.

This change may make starting Skyrizi easier and more convenient by allowing induction to be done at home rather than IV infusions in a clinic. It expands options among IL‑23 p19 inhibitors for people with moderate to...

An at‑home subcutaneous induction option for Skyrizi could make starting this IL‑23 inhibitor easier for many adults with moderate‑to‑severe Crohn’s disease, reducing the need for clinic infusions and possibly improving...

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Risankizumab, IL-23 inhibitor, and Medications.

Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.

This gives adults with moderately to severely active Crohn’s disease a new at-home way to start Skyrizi treatment instead of needing an IV infusion, which can make initiation more convenient and fit into daily life.

This expands how risankizumab (an IL-23 inhibitor) can be started for adults with moderate-to-severe Crohn’s disease, allowing fully at-home, self-administered induction. That may make initiation easier and reduce clinic...

This study indicates pediatric DGBI are common worldwide and are linked to mental-health burden and healthcare use, so better recognition and support could help many children and families.

This analysis suggests delivery method for the same anti‑TNF (infliximab) may affect long‑term clinical and endoscopic outcomes in ileal-predominant Crohn’s disease. If confirmed, route of maintenance dosing could...

An FDA approval of a subcutaneous induction option for risankizumab means adults with moderate-to-severe Crohn's disease can start treatment at home using an on-body injector, which may make starting therapy more...

Definitions of "disease burden" vary a lot, which makes it hard to compare studies or to ensure care and research address what matters most to people with Crohn's. A unified, multidimensional framework could help...

The paper reports a preclinical targeted-delivery formulation that may allow lower systemic exposure to tofacitinib while concentrating drug in inflamed colon tissue—potentially reducing known systemic risks of JAK...